Key facts
- Digostics’s last known valuation is $16.1M (May 2025).
- It has raised $4.3M across 1 recorded rounds; the latest was Seed Round ($674K) in Apr 2023.
- Notable investors include Innovate UK, Collab Novena, TheHill.
- Digostics has filed 1 Form D with the SEC, most recently Jul 2023 ($674K sold to 27 investors).
- Status: Privately Held (backing).
Investors
3- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Digostics
Funding rounds
1 roundsAbout Digostics
Operator of a healthcare company intended to provide home-based diagnostic testing platform for the detection and management of diabetes. The company provides an alternative to traditional in-clinic oral glucose tolerance testing (OGTT) by allowing the test to be performed remotely using its home-testing system and delivers accuracy comparable to laboratory-administered tests, while reducing the operational constraints associated with clinic-based diagnostics, such as staffing demands, sample degradation risks, and processing delays, enabling patients to early identify disease.
- Sector
- Healthcare
- HQ
- Didcot, United Kingdom
- Founded
- 2019
- Employees
- 10
- Website
- digostics.com/
- Ownership
- Privately Held (backing)
Digostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Digostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Digostics in its N-PORT filings yet. We sweep new filings monthly.